Clinical Trial

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose is to evaluate the effectiveness and safety of Surufatinib in patients with osteosarcoma and soft tissue sarcoma after Standard chemotherapy therapy.
Trial Details
NCT Number NCT05106777
Lead Sponsor Sun Yat-sen University
Conditions Sarcoma
Enrollment 47 participants
Start Date 2021-12-10
Primary Completion 2025-12-10 (estimated)
Study Completion 2026-12-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-11